Link Cell Therapies
Link Cell Therapies is a South San Francisco clinical-stage cell therapy company founded by Stanford investigators Robbie Majzner and Crystal Mackall in partnership with Samsara BioCapital, working on the development of safe and effective CAR T agents for patients with solid tumors. The company's logic-gate technology produces AND-gate CAR T cells that require co-expression of two cancer targets before driving cell cytotoxicity, giving greater tumor specificity than existing logic-gate approaches and aiming to avoid off-tumor toxicity. Alongside additional platforms under development, Link is advancing therapeutic programs across solid tumors and certain hematologic cancers, including a dual-targeting AND-gated CAR program (LNK001) directed at clear cell renal cell carcinoma, and in January 2026 entered a strategic collaboration with Johnson & Johnson to develop logic-gate LINK CAR T therapies. Link Cell Therapies publishes no public API, developer portal, or machine-readable interface; this profile captures company identity and probed public-surface posture only.
Index entry only — little beyond a description and a link, and nothing machine-readable enough for an agent to act on without a human reading the site first.
API Evangelist profiles Link Cell Therapies the way a machine reads it — 1 machine-readable artifact, pulled from the provider's own public surface and indexed so a developer, an analyst, or an AI agent can evaluate it against every other provider on the network.
Every provider in the network is reduced to the same set of machine-readable artifacts — OpenAPI contracts, event specifications, GraphQL schemas, runnable collections, pricing and rate-limit signals, security posture, OAuth scopes, and the agent surfaces (MCP servers and skills) that let software drive the API on its own. We profile them because the interface is the part of a company you can actually inspect: it is a truer signal of what a provider does than any marketing page. From those artifacts we compute the Kin Score — Link Cell Therapies scores 10.8/100 (minimal), with a separate agent-readiness read of 4/100 (human only). The full breakdown is below, followed by every artifact we hold — each card links through to its machine-readable definition on apis.io.
Kin Score
This is the API Evangelist rating — a single, repeatable read computed from the artifacts on this page. Green fill is points earned; the red track is points possible, so every bar shows earned-versus-possible at a glance.
Kin Score
How this is scored →scored 2026-07-27 · rubric v0.5
How we profile Link Cell Therapies
Each block below is one kind of artifact we hold for Link Cell Therapies. For each we say what it is and why it earns a place in the profile, then list every one we've indexed — capped at two rows, scroll within the panel for the rest.
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals — the evidence that a provider takes security seriously enough to document it. We profile it because you can't govern what you can't see.
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Every other property we hold for Link Cell Therapies — documentation, portals, status pages, policies, and corporate surface — grouped by the job it does, following the integrator's arc from getting started to running in production.
Agent Surfaces 2
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 1
Pricing, plans, and the legal terms of use
Company 6
The organization behind the API
Other 1
Properties that don't map to a standard resource type
← All providers · Data indexed from github.com/api-evangelist/link-cell-therapies · machine-readable index on apis.io